Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of metabolic syndrome. Hepatic lipotoxicity and inflammation are two key factors driving progression of steatosis to metabolic dysfunction-associated steatohepatitis (MASH). The presence of MASH in...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-15778-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226277358141440 |
|---|---|
| author | Adeyinka Taiwo Himani Thakkar J. Alan Maschek James Cox Scott A. Summers Diana Jalal Ayotunde Dokun William I. Sivitz Bhagirath Chaurasia |
| author_facet | Adeyinka Taiwo Himani Thakkar J. Alan Maschek James Cox Scott A. Summers Diana Jalal Ayotunde Dokun William I. Sivitz Bhagirath Chaurasia |
| author_sort | Adeyinka Taiwo |
| collection | DOAJ |
| description | Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of metabolic syndrome. Hepatic lipotoxicity and inflammation are two key factors driving progression of steatosis to metabolic dysfunction-associated steatohepatitis (MASH). The presence of MASH increases the risk of cardiovascular events, cirrhosis, hepatocellular carcinoma (HCC) and non-liver malignancies. Although MASLD and lipid species have been extensively examined in persons with type 2 diabetes, much less is known in type 1 diabetes. We examined the association of key lipid species with MASLD in individuals with type 1 diabetes. We designed a cross-sectional study of 30 participants with type 1 diabetes recr1uited from our institutional diabetes clinics. All participants had fasting blood drawn for targeted lipidomics and underwent a FibroScan. Those with steatosis score of ≥ 248 as determined by controlled attenuation parameter (CAP) were categorized as cases (n = 17); those with steatosis score < 248 were categorized as controls (n = 13). BMI was significantly higher in cases than controls (P = 0.0007) and used significantly higher 24-h insulin doses than controls (P = 0.004). Cases displayed significantly higher circulating levels of total ceramides (P = 0.02), diacylglycerols (P = 0.0009) and triacylglycerols (P = 0.0004). The two groups displayed similar levels of hexosylceramides, dihydrosphingomyelins, sphingomyelins, and phosphatidylcholines. Similar to previous findings, numerous sphingolipids species, diacylglycerols, and triacylglycerols were found to correlate positively with higher BMI and 24-h insulin dose. Total circulating dihydroceramides, ceramides, diacylglycerols, and triacylglycerols levels significantly correlated with steatosis score (P < 0.05). None of the lipid species correlated with fibrosis score. These results suggest that persons with type 1 diabetes and MASLD have a higher BMI, are likely to be insulin resistant, and display elevated circulating levels of dihydroceramides, ceramides, diacylglycerols, and triacylglycerols, which are strongly associated with the pathogenesis of steatotic liver disease. |
| format | Article |
| id | doaj-art-6829b014999445f6b669c3765e7deb80 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-6829b014999445f6b669c3765e7deb802025-08-24T11:26:33ZengNature PortfolioScientific Reports2045-23222025-08-0115111310.1038/s41598-025-15778-zCharacterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetesAdeyinka Taiwo0Himani Thakkar1J. Alan Maschek2James Cox3Scott A. Summers4Diana Jalal5Ayotunde Dokun6William I. Sivitz7Bhagirath Chaurasia8Department of Internal Medicine, Division of Endocrinology and Metabolism, University of IowaDepartment of Internal Medicine, Division of Endocrinology and Metabolism, University of IowaDepartment of Nutrition and Integrative Physiology, University of UtahDepartment of Biochemistry, University of UtahDepartment of Nutrition and Integrative Physiology, University of UtahDepartment of Internal Medicine, Division of Nephrology, University of IowaDepartment of Internal Medicine, Division of Endocrinology and Metabolism, University of IowaDepartment of Internal Medicine, Division of Endocrinology and Metabolism, University of IowaDepartment of Internal Medicine, Division of Endocrinology and Metabolism, University of IowaAbstract Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of metabolic syndrome. Hepatic lipotoxicity and inflammation are two key factors driving progression of steatosis to metabolic dysfunction-associated steatohepatitis (MASH). The presence of MASH increases the risk of cardiovascular events, cirrhosis, hepatocellular carcinoma (HCC) and non-liver malignancies. Although MASLD and lipid species have been extensively examined in persons with type 2 diabetes, much less is known in type 1 diabetes. We examined the association of key lipid species with MASLD in individuals with type 1 diabetes. We designed a cross-sectional study of 30 participants with type 1 diabetes recr1uited from our institutional diabetes clinics. All participants had fasting blood drawn for targeted lipidomics and underwent a FibroScan. Those with steatosis score of ≥ 248 as determined by controlled attenuation parameter (CAP) were categorized as cases (n = 17); those with steatosis score < 248 were categorized as controls (n = 13). BMI was significantly higher in cases than controls (P = 0.0007) and used significantly higher 24-h insulin doses than controls (P = 0.004). Cases displayed significantly higher circulating levels of total ceramides (P = 0.02), diacylglycerols (P = 0.0009) and triacylglycerols (P = 0.0004). The two groups displayed similar levels of hexosylceramides, dihydrosphingomyelins, sphingomyelins, and phosphatidylcholines. Similar to previous findings, numerous sphingolipids species, diacylglycerols, and triacylglycerols were found to correlate positively with higher BMI and 24-h insulin dose. Total circulating dihydroceramides, ceramides, diacylglycerols, and triacylglycerols levels significantly correlated with steatosis score (P < 0.05). None of the lipid species correlated with fibrosis score. These results suggest that persons with type 1 diabetes and MASLD have a higher BMI, are likely to be insulin resistant, and display elevated circulating levels of dihydroceramides, ceramides, diacylglycerols, and triacylglycerols, which are strongly associated with the pathogenesis of steatotic liver disease.https://doi.org/10.1038/s41598-025-15778-zFatty liverSteatosisDiabetes mellitusType 1Cross-sectional studyInsulin resistance |
| spellingShingle | Adeyinka Taiwo Himani Thakkar J. Alan Maschek James Cox Scott A. Summers Diana Jalal Ayotunde Dokun William I. Sivitz Bhagirath Chaurasia Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes Scientific Reports Fatty liver Steatosis Diabetes mellitus Type 1 Cross-sectional study Insulin resistance |
| title | Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes |
| title_full | Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes |
| title_fullStr | Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes |
| title_full_unstemmed | Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes |
| title_short | Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes |
| title_sort | characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes |
| topic | Fatty liver Steatosis Diabetes mellitus Type 1 Cross-sectional study Insulin resistance |
| url | https://doi.org/10.1038/s41598-025-15778-z |
| work_keys_str_mv | AT adeyinkataiwo characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT himanithakkar characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT jalanmaschek characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT jamescox characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT scottasummers characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT dianajalal characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT ayotundedokun characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT williamisivitz characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes AT bhagirathchaurasia characterizingplasmalipidspeciesinmetabolicdysfunctionassociatedsteatoticliverdiseaseinpersonswithtype1diabetes |